amendment:
  amendment_details: '<p>Amendment Details:  This protocol has not been amended previously.</p>

    <p>Overall Rationale for the Amendment:</p>

    <p>The overall rationale (one primary driver) for the changes implemented in the
    protocol amendment should be provided. In addition, provide a high-level description
    of the change(s) and a brief scientific rationale for specific items outlined
    in the table provided (eg, changes to individual inclusion/exclusion criteria).
    See Appendix 9, Protocol Amendment History for examples of format and green text
    for sample content.</p>

    <p>Updates to address safety concern & align with product guidelines.</p>'
  robustness_impact: false
  robustness_impact_reason: ''
  safety_impact: false
  safety_impact_reason: ''
miscellaneous:
  medical_expert_contact: ''
  sae_reporting_method: ''
  sponsor_signatory: ''
title_page:
  amendment_details: ''
  amendment_identifier: 'I8R-JE-IGBJ(a)

    '
  amendment_scope: 'Global

    '
  compound_codes: 'LY900018

    '
  compound_names: 'Glucagon

    '
  manufacturer_name_and_address: 'On file with sponsor.

    '
  medical_expert_contact: ''
  original_protocol: 'No

    '
  regulatory_agency_identifiers: 'NCT03421379

    '
  sae_reporting_method: ''
  sponsor_approval_date: '2017-10-26T00:00:00'
  sponsor_confidentiality: ''
  sponsor_name_and_address: 'Eli Lilly Japan K.K

    Japan

    '
  sponsor_signatory: ''
